Drug Trial Radar · NCT06727604
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Dec 17, 2024
Primary completion
Jun 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- Immunovant Sciences GmbHIndustry
- Sponsor type
- Industry
- First posted
- Dec 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine \[T3\] or free triiodothyronine \[FT3\]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.
Conditions
- Graves' Disease
Interventions
IMVT-1402Drug
600 mg SC QW for 52 weeks
IMVT-1402Drug
600 mg SC QW for 26 weeks followed by Placebo SC QW for 26 weeks
PlaceboDrug
SC QW for 52 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants who are euthyroid (local laboratory T3 [Total T3 or FT3], FT4, and TSH values within normal limits) and off ATD at Week 26Time frame: Week 26
Locations
134 sites in 10 countries. Site status is shown where the registry gives one.
Site Number - 1032
Phoenix, Arizona · Withdrawn
Site Number - 1036
Phoenix, Arizona · Recruiting
Site Number - 1061
Huntington Beach, California · Recruiting
Site Number - 1001
Los Angeles, California · Recruiting
Site Number - 1047
Los Angeles, California · Recruiting
Site Number - 1062
Orange, California · Recruiting
Site Number - 1046
Sacramento, California · Recruiting
Site Number - 1034
San Francisco, California · Recruiting
Site Number - 1035
Santa Clarita, California · Withdrawn
Site Number - 1005
Torrance, California · Recruiting
Site Number - 1006
Walnut Creek, California · Withdrawn
Site Number - 1013
Englewood, Colorado · Recruiting
Site Number - 1010
Newark, Delaware · Recruiting
Site Number - 1040
Washington D.C., District of Columbia · Recruiting
Site Number - 1029
Clearwater, Florida · Recruiting
Site Number - 1055
Jacksonville, Florida · Recruiting
Site Number - 1056
Jacksonville, Florida · Recruiting
Site Number - 1028
Miami, Florida · Recruiting
Site Number - 1065
Miami, Florida · Recruiting
Site Number - 1064
Ocoee, Florida · Recruiting
Site Number - 1011
Orlando, Florida · Withdrawn
Site Number - 1016
Port Charlotte, Florida · Recruiting
Site Number - 1012
West Palm Beach, Florida · Withdrawn
Site Number - 1038
Atlanta, Georgia · Recruiting
Site Number - 1053
Macon, Georgia · Recruiting
Site Number - 1020
Stockbridge, Georgia · Withdrawn
Site Number - 1027
Indianapolis, Indiana · Recruiting
Site Number - 1041
Kansas City, Kansas · Recruiting
Site Number - 1045
Bowling Green, Kentucky · Recruiting
Site Number - 1054
Florence, Kentucky · Recruiting
Site Number - 1063
Metairie, Louisiana · Recruiting
Site Number - 1022
New Orleans, Louisiana · Recruiting
Site Number - 1048
Shreveport, Louisiana · Recruiting
Site Number - 1023
Baltimore, Maryland · Recruiting
Site Number - 1026
Boston, Massachusetts · Recruiting
Site Number - 1018
Farmington Hills, Michigan · Recruiting
Site Number - 1069
Flint, Michigan · Recruiting
Site Number - 1008
Rochester, Minnesota · Recruiting
Site Number - 1068
Gulfport, Mississippi · Recruiting
Site Number - 1017
Omaha, Nebraska · Recruiting
Showing 40 of 134 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.